KOS 2187

Drug Profile

KOS 2187

Alternative Names: KOS-2187; PF-04548043; PF-4548043

Latest Information Update: 14 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kosan Biosciences
  • Developer Pfizer
  • Class Gastrokinetics
  • Mechanism of Action Motilin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux

Most Recent Events

  • 17 Oct 2008 Updated MoA
  • 27 Jun 2008 Kosan has been acquired by Bristol-Myers Squibb
  • 06 Aug 2007 Phase-I clinical trials in Diabetic gastroparesis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top